MET and non-small cell lung carcinoma: The significance of MET amplification in the context of MET∆ex14 alterations is unclear, but recent data from a prospective trial [15, 16, 17] indicate that it does affect response to MET‐TKIs, endorsing MET∆ex14 as a truly separate driver in NSCLC.